Lipoprotein-associated phospholipase A2 is associated with atherosclerotic stroke risk: The Northern Manhattan Study

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Katan, Mira ^a,b   Moon, Yeseon P ^a   Paik, Myunghee C ^c   Wolfert, Robert L ^d   Sacco, Ralph L ^e   Elkind, Mitchell S V ^a,c  

^a Department of Neurology Columbia University College of Physicians and Surgeons ^*  (United States)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c Department of Biostatistics Mailman School of Public Health Columbia University ^*  (United States)

^d diaDexus Inc   (United States)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE;

AGED; ARTICLE; BRAIN ATHEROSCLEROSIS; BRAIN ISCHEMIA; CARDIOEMBOLIC STROKE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; ETHNICITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR;

AGED; ATHEROSCLEROSIS; BRAIN ISCHEMIA; FEMALE; HUMANS; INCIDENCE; MALE; NEW YORK; PHOSPHOLIPASES A2; RISK FACTORS; STROKE;

EID: 84897480269     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083393     Document Type: Article

References (33)

1. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, et al. (2011) Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 123: e18-e209.
2. Wilensky RL, Shi Y, Mohler ER 3rd, Hamamdzic D, Burgert ME, et al. (2008) Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med 14: 1059-1066.
3. Serruys PW, Garcia-Garcia HM, Buszman P, Erne P, Verheye S, et al. (2008) Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 118: 1172-1182.
4. Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, et al. (2010) Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 375: 1536-1544.
5. http://clinicaltrials.gov/ct2/show/NCT01000727). (accesed 2013) The Stabilization of plaques using Darapladib- Thrombolysis in Myocardial Infarction 52 Trial (SOLID-TIMI 52).
6. http://clinicaltrials.gov/ct2/show/NTC00799903). (accessed 2013) The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial (STABILITY).
7. Gorelick PB (2008) Lipoprotein-associated phospholipase A2 and risk of stroke. Am J Cardiol 101: 34F-40F.
8. Elkind MS, TaiW, Coates K, Paik MC, Sacco RL (2009) Lipoprotein- associated phospholipase A2 activity and risk of recurrent stroke. Cerebrovasc Dis 27: 42-50.
9. Elkind MS, Tai W, Coates K, Paik MC, Sacco RL (2006) High-sensitivity Creactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med 166: 2073-2080. (Pubitemid 44631394)
10. Elkind MS, Sciacca RR, Boden-Albala B, Rundek T, Paik MC, et al. (2005) Relative elevation in baseline leukocyte count predicts first cerebral infarction. Neurology 64: 2121-2125. (Pubitemid 40881005)
11. Gentry EM, Kalsbeek WD, Hogelin GC, Jones JT, Gaines KL, et al. (1985) The behavioral risk factor surveys: II. Design, methods, and estimates from combined state data. American journal of preventive medicine 1: 9-14. (Pubitemid 16154925)
12. Sacco RL, Anand K, Lee HS, Boden-Albala B, Stabler S, et al. (2004) Homocysteine and the risk of ischemic stroke in a triethnic cohort: the NOrthern MAnhattan Study. Stroke; a journal of cerebral circulation 35: 2263-2269. (Pubitemid 39311247)
13. Organisation WH (1983) Proposal for the multinational monitoring of trends and determinants in cardiovascular disease(MONICA project). WHO/MNC/821 Rev 1.
14. Gan R, Sacco RL, Kargman DE, Roberts JK, Boden-Albala B, et al. (1997) Testing the validity of the lacunar hypothesis: the Northern Manhattan Stroke Study experience. Neurology 48: 1204-1211. (Pubitemid 27240535)
15. Adams HP, Jr., Bendixen BH, Kappelle LJ, Biller J, Love BB, et al. (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke; a journal of cerebral circulation 24: 35-41. (Pubitemid 23014379)
16. (1995) Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration. Lancet 346: 1647-1653.
17. Bang OY, Saver JL, Liebeskind DS, Pineda S, Ovbiagele B (2008) Association of serum lipid indices with large artery atherosclerotic stroke. Neurology 70: 841-847. (Pubitemid 351367520)
18. Delgado P, Chacon P, Penalba A, Pelegri D, Garcia-Berrocoso T, et al. (2012) Lipoprotein-associated phospholipase a(2) activity is associated with large-artery atherosclerotic etiology and recurrent stroke in TIA patients. Cerebrovascular diseases 33: 150-158.
19. Mannheim D, Herrmann J, Versari D, Gossl M, Meyer FB, et al. (2008) Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques. Stroke; a journal of cerebral circulation 39: 1448-1455.
20. Brilakis ES, Khera A, McGuire DK, See R, Banerjee S, et al. (2008) Influence of race and sex on lipoprotein-associated phospholipase A2 levels: observations from the Dallas Heart Study. Atherosclerosis 199: 110-115. (Pubitemid 351842698)
21. Oei HH, van der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, et al. (2005) Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 111: 570-575. (Pubitemid 40216483)
22. Persson M, Berglund G, Nelson JJ, Hedblad B (2008) Lp-PLA2 activity and mass are associated with increased incidence of ischemic stroke: a population-based cohort study from Malmo, Sweden. Atherosclerosis 200: 191-198.
23. Cook NR, Paynter NP, Manson JE, Martin LW, Robinson JG, et al. (2012) Clinical utility of lipoprotein-associated phospholipase A(2) for cardiovascular disease prediction in a multiethnic cohort of women. Clin Chem 58: 1352-1363.
24. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, et al. (2005) Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med 165: 2479-2484. (Pubitemid 41720009)
25. Markus HS, Khan U, Birns J, Evans A, Kalra L, et al. (2007) Differences in stroke subtypes between black and white patients with stroke: the South London Ethnicity and Stroke Study. Circulation 116: 2157-2164. (Pubitemid 350060353)
26. Sacco RL, Kargman DE, Gu Q, Zamanillo MC (1995) Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction. The Northern Manhattan Stroke Study. Stroke; a journal of cerebral circulation 26: 14-20.
27. Wityk RJ, Lehman D, Klag M, Coresh J, Ahn H, et al. (1996) Race and sex differences in the distribution of cerebral atherosclerosis. Stroke; a journal of cerebral circulation 27: 1974-1980. (Pubitemid 26372566)
28. Wong KS, Huang YN, Gao S, Lam WW, Chan YL, et al. (1998) Intracranial stenosis in Chinese patients with acute stroke. Neurology 50: 812-813.
29. De Silva DA, Woon FP, Lee MP, Chen CP, Chang HM, et al. (2007) South Asian patients with ischemic stroke: intracranial large arteries are the predominant site of disease. Stroke; a journal of cerebral circulation 38: 2592-2594. (Pubitemid 47329642)
30. Caplan LR, Gorelick PB, Hier DB (1986) Race, sex and occlusive cerebrovascular disease: a review. Stroke; a journal of cerebral circulation 17: 648-655. (Pubitemid 16066533)
31. Petty GW, Brown RD, Jr., Whisnant JP, Sicks JD, O'Fallon WM, et al. (1999) Ischemic stroke subtypes: a population-based study of incidence and risk factors. Stroke; a journal of cerebral circulation 30: 2513-2516.
32. Willey JZ, Xu Q, Boden-Albala B, Paik MC, Moon YP, et al. (2009) Lipid profile components and risk of ischemic stroke: the Northern Manhattan Study (NOMAS). Archives of neurology 66: 1400-1406.
33. Oliver LK, Voskoboev N, Heser D, McConnell JP, Hodel-Hanson S, et al. (2011) Assessment of clinical performance without adequate analytical validation: A prescription for confusion. Clinical biochemistry 44: 1247-1252.